US 12,201,441 B2
Biomarkers of neuropathic pain
Clifford J. Woolf, Newton, MA (US); Alban A. Latremoliere, Baltimore, MD (US); Thomas E. Scammell, Wellesley, MA (US); and Chloe M. Alexandre, Baltimore, MD (US)
Assigned to Children's Medical Center Corporation, Boston, MA (US); and Beth Israel Deaconess Medical Center, Inc., Boston, MA (US)
Appl. No. 17/251,755
Filed by Children's Medical Center Corporation, Boston, MA (US); and Beth Israel Deaconess Medical Center, Inc., Boston, MA (US)
PCT Filed Jun. 13, 2019, PCT No. PCT/US2019/037063
§ 371(c)(1), (2) Date Dec. 11, 2020,
PCT Pub. No. WO2019/241564, PCT Pub. Date Dec. 19, 2019.
Claims priority of provisional application 62/684,599, filed on Jun. 13, 2018.
Prior Publication US 2021/0386365 A1, Dec. 16, 2021
Int. Cl. A61B 5/00 (2006.01); A61B 5/374 (2021.01); A61B 5/397 (2021.01); A61K 31/195 (2006.01); A61K 31/55 (2006.01); A61P 29/00 (2006.01)
CPC A61B 5/4809 (2013.01) [A61B 5/374 (2021.01); A61B 5/397 (2021.01); A61B 5/4812 (2013.01); A61B 5/4824 (2013.01); A61K 31/195 (2013.01); A61K 31/55 (2013.01); A61P 29/00 (2018.01)] 13 Claims
OG exemplary drawing
 
1. A method of treating a subject having neuropathic pain, the method comprising:
detecting the frequency of brief awakenings (BAs) during sleep of the subject, wherein the BAs last less than 30s;
determining that the frequency of BAs is increased compared to a reference level; and
administering a therapeutic agent to the subject, thereby treating neuropathic pain in the subject.